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Radiation therapy (RT) plays a definitive part of anti-
cancer therapy for the majority of common cancers but
for many patients, metastatic disease and local recur-
rence are common and the outlook remains poor. New
more effective RT combination approaches are urgently
required that decrease local and distant recurrence to
improve outcomes.
Using a range of established syngeneic tumor models
(CT26 (colorectal), 4T1 (breast) or 4434 (BRafV600E
p16-/- melanoma) we sought to determine the impact of
fractionated RT (fRT) on the tumor microenvironment.
Our data reveal that treatment with a course of fRT
leads to significant upregulation of tumor cell expression
of PD-L1 in vivo. Through cellular depletion studies we
determined that this RT-mediated increase in tumor cell
expression of PD-L1 was dependent on CD8+ T cells.
Furthermore, ShRNA-mediated silencing of tumor cell
IFNgR1 expression or administration of an IFNg deplet-
ing mAb phenocopied the depletion of CD8+ T cells.
Taken together, these data demonstrate that adaptive
upregulation of tumor cell PD-L1 following treatment
with low-dose fRT is mediated by tumor infiltrating
CD8+ T cell production of IFNg. Using a dual tumor
model our data reveal that this adaptive upregulation is
restricted to the irradiated tumor site with no change in
tumor cell PD-L1 expression detected in tumors situated
outside of the ionizing radiation field, signifying that
treatment with RT alone may not generate systemic
tumor antigen-specific responses. Administration of
either an anti-PD-1 or anti-PD-L1 mAb in combination
with fRT was found to substantially improve survival
when compared to either monotherapy alone. In addi-
tion, abscopal responses were observed on tumors out-
side of the RT treatment field. Our data reveal that up
to 60% of mice undergo a complete response following
combination therapy and are protected against tumor
rechallenge by the generation of long-term immunologi-
cal memory. Furthermore, we found that scheduling of
anti-PD-L1 mAb relative to the delivery of fRT appeared
important to therapeutic outcome with concomitant but
not sequential administration required for improved
survival.
Tumor cell PD-L1 expression following treatment
with fRT appears to be a mechanism of adaptive immu-
nological resistance which may potentially contribute to
fRT treatment failure. This study demonstrates the
potential for enhancing the efficacy of conventional RT
through blockade of the PD-1/PD-L1 axis, but sequen-
cing is critical, providing important new insights for
clinical evaluation.
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